Intervista alle vincitrici della terza edizione del bando Fondazione Gianni Bonadonna / Fondazione AIRC per la ricerca sul cancro per borse di studio per l’estero, Dr.ssa Chiara Corti e Dr.ssa Caterina Sposetti, MD fondazionebonadonna.org/video/ #fondazionebonadonna #airc #cancer #fundingopportunity #fellowship

Tremendous presentation by Nancy Lin, MD on TDXd in HER2+ MBC with brain mets. RR in pts with CNS dz is 52% overall and > 70% in CNS, essentially the same as those without CNS mets. That is, it works equally well in the CNS as elsewhere in the body!

Some HER2+ tumors melt upon dual anti-HER2 Rx; others require chemo, or don’t respond to anything. Dissecting them, a key challenge with huge clinical impact. Find the latest understanding on anti-HER2 Rx tailoring in our latest article, led by Ada Waks. nature.com/articles/s4157…

DESTINY-Breast12 Data Support T-DXd Use in HER2+ Breast Cancer, Irrespective of Brain Mets Nancy Lin, MD Dana-Farber News ESMO - Eur. Oncology #ESMO24 #bcsm onclive.com/view/destiny-b…

Don't miss Dr. Paolo Tarantino's (Paolo Tarantino) at the #ESMO24 Industry Satellite Symposium 🗓️ Saturday, Sept 14th ⏰ 13:00 - 14:30 CEST (7:00 am EST) 📍Salamanca Auditorium - Hall 5

Congratulations to Nancy Lin, MD and the DB-12 team! Incredible data for T-DXd in pts with brain mets! Dana-Farber’s Breast Oncology Center #ESMO24 OncoAlert

Our review on dual HER2 inhibition is out!! Thanks to NatureRevClinOncol for this opportunity and to all co-authors for a wonderful collaboration!! Paolo Tarantino Sara Tolaney Aleix Prat #PrecisionOncology

🎉 Excited to share our latest review in Nature Reviews Clinical Oncology! 🎉 NatureRevClinOncol 📖 We dive into the latest on dual #HER2 inhibition in #BreastCancer—exploring synergy, patient selection, and resistance. 🔬💥 Big steps forward in personalized treatment for

Does the addition of OFS improve the DFS and OS in HR+/HER2+ early breast cancer? Yes it does according to the exploratory analysis of HERA trial as presented at the #ESMO2024 OncoAlert Erika Hamilton, MD Hope Rugo Nancy Lin, MD Sara Tolaney

Important analysis by Elise Dumas showing the decreased DFS of HR+BC in very young patients, who also demonstrate diminished persistence to ET. #ESMO24

NATALEE: Analysis at 3 yrs in younger pts (<40 vs ≥40) Age<40, iDFS at 3 yrs: 90.1 vs 85%, delta 5.1% Age>40 90.7 vs 87.9, delta 2.8% Addition of ribociclib in younger pts adds benefit Lower discontinuation in younger pts Similar QOL seen OncoAlert #ESMO24 #bcsm Sherene Loi, MD

HERA: OFS improved 10 yr DFS and OS if premenopausal and age <50 + recv'd trastuzumab Kevin Kalinsky, MD, MS puts this in perspective in setting of a changed landscape w/newer HER2-directed tx, + recommends consideration of OFS in younger pts w/ high risk HER2+ BC #ESMO24 OncoAlert

Registry of stage 1 TNBC (>1100 pts) pCR: 57.3% pCR associated w/ better OS (HR 0.29) OncoAlert #bcsm #ESMO24

TNBCDX: assay to predict pCR and DFS Data presented to look at validation (ADAPT-TN, and MMJ-CAR-2014 studies), n=418 pCR score associated with pCR OR 1.34 (independent of TIL) Low Risk score iDFS 89.9% vs High risk iDFS 69.4% OncoAlert #ESMO24

ER-low (ER =1-9%) behaves more or less as TNBC. The PROMENADE RWD french trial shows that the addition of neoadjuvant Pembrolizumab in ER-LOW improves pCR using the KN522 regime. #ESMO2024 #ESMO24 OncoAlert Paolo Tarantino Sara Tolaney ESMO - Eur. Oncology Erika Hamilton, MD

SUBITO: Adding olaparib to intensified chemo didn't improve OS in stage 3 HRD BC OncoAlert #bcsm #ESMO24

ISPY2.2 Dato-DXd+ durva, results of blocks A thru C: pCR 50% n=106 (n=42 HR+, n=64 TNBC) pCR 62% TNBC, 79% Immune + HR-HER2-Immune-DPD- :met graduation criteria OncoAlert #ESMO24

ISPY2.2 Preop Dato-DXd Blocks A-C pCR 38.1% (~1/2 occurred after block A) OncoAlert #bcsm #ESMO24

TILs and OS in ShortHER TIL predicts OS in early HER2+ breast cancer TIL≥20% who de-escalated trastuzumab duration are not exposed to excess risk of death OncoAlert #bcsm #ESMO24

In the POSITIVE trial 2/3 of the patients breastfed after delivery, with the majority having undergone breast conservative surgery (BCS). The stoppage of ET to become pregnant and breastfeeding didn't lead to poor survival #ESMO24 Fedro Peccatori MD, PhD Matteo Lambertini, MD PhD OncoAlert Sara Tolaney